Definition And Pathogenesis

• Severe combined immunodeficiency (SCID) represents the most severe form of primary immune deficiency.
• It is a true pediatric immunologic emergency.
• The disorder is caused by diverse pathogenic gene variants.
• These variants lead to the profound absence of T-cell and B-cell function.
• The fundamental defect disrupts lymphoid cell development in both the thymus and peripheral tissues.
• Affected infants present with very small thymuses.
• The thymus contains no thymocytes.
• The thymus lacks corticomedullary distinction.
• It is completely devoid of Hassall's corpuscles.
• The thymic epithelium itself appears histologically normal.
• Peripheral lymphoid structures are also severely affected.
• The follicular and paracortical areas of the spleen are depleted of lymphocytes.
• Lymph nodes, tonsils, adenoids, and Peyer patches are absent or extremely underdeveloped.
• Without definitive immunologic reconstitution, death usually occurs during the first year of life.
• The disease is almost invariably fatal before 2 years of age without proper treatment.

Genetic Classification And Phenotypes

• SCID exhibits significant genetic heterogeneity.
• The disorders are primarily categorized based on the presence or absence of specific lymphocyte populations.
• These populations include T cells, B cells, and Natural Killer (NK) cells.
• The four most common types of SCID are the X-linked form, autosomal recessive RAG1 and RAG2 deficiencies, and adenosine deaminase (ADA) deficiency.

T- B+ Severe Combined Immunodeficiency

• This category is characterized by absent T cells but normal or elevated numbers of B cells.

T- B- Severe Combined Immunodeficiency

• This category is characterized by the profound absence of both mature T cells and B cells.

Clinical Manifestations

Infectious Manifestations

• Infants typically present with severe infections during early infancy if not detected by newborn screening.
• Common initial presentations include chronic diarrhea, recurrent pneumonia, persistent otitis media, sepsis, and severe cutaneous infections.
• Patients demonstrate an extreme susceptibility to opportunistic pathogens.
• Severe oral thrush from Candida albicans is a classic hallmark.
• Pulmonary infections are frequently caused by Pneumocystis jiroveci (PJP).
• Common respiratory viruses cause severe, life-threatening illness.
• These viral agents include parainfluenza 3 virus, adenovirus, respiratory syncytial virus (RSV), cytomegalovirus (CMV), and Epstein-Barr virus (EBV).
• Administration of live-attenuated vaccines results in life-threatening, disseminated vaccine-strain infections.
• Disseminated bacille Calmette-Guérin (BCG) infection is a frequent presenting feature in regions where the vaccine is administered at birth.
• Other contraindicated live vaccines include oral polio virus, rotavirus, measles-mumps-rubella-varicella (MMRV), and yellow fever vaccines.

Non-Infectious And Syndromic Features

• Infants with SCID completely lack the cellular immunity required to reject foreign tissues.
• Transplacental passage of maternal T lymphocytes during pregnancy can cause severe maternal engraftment graft-versus-host disease (GVHD),.
• Maternal engraftment GVHD manifests with a generalized rash, hepatosplenomegaly, intractable diarrhea, and the uncontrolled expansion of allogeneic cells.
• Omenn syndrome is a specific variant caused by hypomorphic pathogenic variants in SCID-associated genes.
• These hypomorphic variants allow the generation of a few oligoclonal T cells.
• These autologous cells expand in an unregulated manner and attack host tissues.
• Omenn syndrome clinically mimics GVHD.
• It presents with severe generalized erythroderma, scaly desquamating skin, alopecia, massive lymphadenopathy, hepatosplenomegaly, and intractable diarrhea.
• Laboratory features of Omenn syndrome uniquely include striking eosinophilia and massively elevated serum IgE levels.
• Unirradiated blood transfusions can introduce viable donor T-lymphocytes into the infant.
• This iatrogenic exposure uniformly causes fatal transfusion-associated GVHD.
• Symptoms of transfusion-associated GVHD include fever, maculopapular rash, Coombs-positive hemolytic anemia, thrombocytopenia, and protein-losing enteropathy.

Diagnostic Evaluation

Newborn Screening

• Newborn screening has dramatically improved survival rates by allowing early diagnosis and treatment prior to the onset of systemic infections.
• The screening assay utilizes a quantitative polymerase chain reaction (PCR) to measure T-cell receptor excision circles (TRECs) from dried blood spots.
• TRECs are episomal DNA byproducts formed during the V(D)J rearrangement of T-cell receptor genes.
• TRECs do not replicate during cell division.
• They serve as a highly accurate biomarker for enumerating recent thymic emigrants.
• A low or absent TREC count identifies infants with severe T-cell lymphopenia and mandates immediate immunologic evaluation.
• Kappa excision circles (KRECs) are generated during B-cell development.
• Assaying KRECs simultaneously with TRECs allows for the identification of broader SCID phenotypes and congenital agammaglobulinemia.

Laboratory Investigations

• A complete blood count typically reveals persistent and profound lymphopenia.
• However, a normal absolute lymphocyte count does not reliably rule out SCID.
• A falsely normal count can occur due to the uncontrolled proliferation of maternal T cells, autologous B cells, or NK cells.
• Flow cytometry is mandatory to precisely quantitate lymphocyte subsets, including T cells, B cells, and NK cells.
• Flow cytometric analysis of CD45 isoforms differentiates naive T cells (CD45RA) from memory T cells (CD45RO).
• A predominance of memory T cells strongly suggests maternal engraftment or Omenn syndrome.
• Identification of a limited T-cell receptor repertoire is also helpful in the diagnosis of Omenn syndrome.
• Functional T-cell evaluation is conducted through lymphocyte proliferation assays.
• A proliferative response to the mitogen phytohemagglutinin (PHA) of less than 10% of a normal control confirms severe combined immunodeficiency.
• Fluorescence in situ hybridization (FISH) targeting the X and Y chromosomes can be utilized in male infants to confirm the presence of engrafted maternal (XX) T cells.
• Definitive diagnosis requires targeted gene sequencing using a primary immunodeficiency gene panel to identify the specific pathogenic variant.
• Genetic diagnosis is critical for guiding conditioning regimens and evaluating gene therapy options.
• Early identification of specific pathogenic variants associated with increased radiation sensitivity helps avoid or reduce dosages of conditioning agents.

Management And Treatment

Supportive Care And Infection Mitigation

• SCID constitutes a medical emergency requiring immediate strict isolation to limit exposure to infectious agents.
• The number of people in contact with the infant must be strictly limited.
• Breastfeeding should be withheld until the CMV and EBV statuses of both the mother and the infant are definitively established.
• Infection can be transmitted via breast milk.
• Immunoglobulin replacement therapy is warranted immediately at diagnosis.
• Maternally derived IgG rapidly wanes after birth, necessitating ongoing immunoglobulin therapy to prevent bacterial illnesses.
• Antimicrobial prophylaxis must be initiated promptly at 4 to 6 weeks of age.
• Prophylaxis regimens must cover Pneumocystis jiroveci alongside specific viral and fungal pathogens.
• Administration of palivizumab is recommended during respiratory syncytial virus (RSV) season for children under 2 years of age to prevent severe lower respiratory tract disease.
• Administration of any live-attenuated viral or bacterial vaccines is strictly contraindicated,.
• To prevent fatal transfusion-associated GVHD, all administered blood products must be exclusively irradiated or frozen.

Definitive Curative Therapies

• Allogeneic hematopoietic stem cell transplantation (HSCT) remains the most important and effective therapy for SCID.
• Survival rates approach 95% when HSCT is performed optimally within the first 100 days of life.
• Outcomes are highly favorable if performed prior to the onset of systemic opportunistic infections.
• Transplantation utilizing an HLA-identical sibling donor is preferred and offers the highest probability of survival,.
• Infants with SCID who lack residual NK cell activity or maternal T-cell engraftment can sometimes receive HSCT without any preceding myeloablative conditioning regimen.
• In these unconditioned cases, the donor lymphoid cells are usually the only elements that engraft.
• Gene therapy utilizing ex vivo gene transfer to autologous hematopoietic stem cells has demonstrated significant success for X-linked SCID and ADA-SCID.
• Modern clinical trials utilize lentiviral vectors.
• The transition to lentiviral vectors has successfully minimized the risk of insertional mutagenesis and secondary leukoproliferative complications associated with earlier retroviral therapies.
• For patients with ADA-SCID, regular intramuscular injections of polyethylene glycol-modified adenosine deaminase (PEG-ADA) can be utilized.
• Enzyme replacement therapy provides some immune restoration, although it is not as robust or effective as HSCT or gene therapy.